Literature DB >> 19837769

Using cerebral white matter for estimation of nondisplaceable binding of 5-HT1A receptors in temporal lobe epilepsy.

Giampiero Giovacchini1, Shielah Conant, Peter Herscovitch, William H Theodore.   

Abstract

UNLABELLED: The estimation of nondisplaceable binding from cerebellar white matter, rather than from whole cerebellum, was proposed for the PET tracer carbonyl-(11)C-WAY-100635 (N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridyl)cyclohexanecarboxamidel]) because of the heterogeneity of total ligand binding in this region. For the 5-hydroxytryptamine receptor 1A (5-HT(1A)) antagonist (18)F-N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-N-2-pyridyl)trans-4-fluorocyclohexanecarboxamide ((18)F-FCWAY), the estimation of nondisplaceable binding from cerebellum (V(ND)) may be additionally biased by spillover of (18)F-fluoride activity from skull. We aimed to assess the effect of using cerebral white matter as reference region on detection of group differences in 5-HT(1A) binding with PET and (18)F-FCWAY.
METHODS: In 22 temporal lobe epilepsy patients (TLE) and 10 healthy controls, (18)F-FCWAY distribution volume in cerebral white matter (V(WM)) was computed using an extrapolation method as part of a partial-volume correction (PVC) algorithm. To assess the feasibility of applying this method to clinical studies in which PVC is not performed, V(WM) was also calculated by placing circular, 6-mm-diameter regions of interest (ROIs) in the centrum semiovalis on parametric images. Binding potentials were BP(F) = (V(T) - V(ND))/f(P) and BP(F-WM) = (V(T) - V(WM))/f(P), where V(T) is total distribution volume and f(P) = (18)F-FCWAY plasma free fraction. Statistical analysis was performed using t tests and linear regression.
RESULTS: In the whole group, V(WM) was 14% +/- 19% lower than V(ND) (P < 0.05). V(WM)/f(P) was significantly (P < 0.05) lower in patients than in controls. All significant (P < 0.05) reductions of 5-HT(1A) receptor availability in TLE patients detected by BP(F) were also detected using BP(F-WM). Significant (P < 0.05) reductions of 5-HT(1A) specific binding were detected by BP(F-WM), but not BP(F), in ipsilateral inferior temporal cortex, contralateral fusiform gyrus, and contralateral amygdala. However, effect sizes were similar for BP(F-WM) and BP(F). The value of V(WM) calculated with the ROI approach did not significantly (P > 0.05) differ from that calculated with the extrapolation approach (0.67 +/- 0.32 mL/mL and 0.72 +/- 0.34 mL/mL, respectively).
CONCLUSION: Cerebral white matter can be used for the quantification of nondisplaceable binding of 5-HT(1A) without loss of statistical power for detection of regional group differences. The ROI approach is a good compromise between computational complexity and sensitivity to spillover of activity, and it appears suitable to studies in which PVC is not performed. For (18)F-FCWAY, this approach has the advantage of avoiding spillover of (18)F-fluoride activity onto the reference region.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837769      PMCID: PMC3059591          DOI: 10.2967/jnumed.109.063743

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  37 in total

1.  Adaptive fuzzy segmentation of magnetic resonance images.

Authors:  D L Pham; J L Prince
Journal:  IEEE Trans Med Imaging       Date:  1999-09       Impact factor: 10.048

2.  Significance of cerebellar atrophy in intractable temporal lobe epilepsy: a quantitative MRI study.

Authors:  E K Sandok; T J O'Brien; C R Jack; E L So
Journal:  Epilepsia       Date:  2000-10       Impact factor: 5.864

3.  A global optimisation method for robust affine registration of brain images.

Authors:  M Jenkinson; S Smith
Journal:  Med Image Anal       Date:  2001-06       Impact factor: 8.545

4.  Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635.

Authors:  Ramin V Parsey; Maria A Oquendo; Norman R Simpson; R Todd Ogden; Ronald Van Heertum; Victoria Arango; J John Mann
Journal:  Brain Res       Date:  2002-11-08       Impact factor: 3.252

5.  The PET radioligand [carbonyl-(11)C]desmethyl-WAY-100635 binds to 5-HT(1A) receptors and provides a higher radioactive signal than [carbonyl-(11)C]WAY-100635 in the human brain.

Authors:  Bengt Andrée; Christer Halldin; Victor W Pike; Roger N Gunn; Hans Olsson; Lars Farde
Journal:  J Nucl Med       Date:  2002-03       Impact factor: 10.057

6.  PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy.

Authors:  M T Toczek; R E Carson; L Lang; Y Ma; M V Spanaki; M G Der; S Fazilat; L Kopylev; P Herscovitch; W C Eckelman; W H Theodore
Journal:  Neurology       Date:  2003-03-11       Impact factor: 9.910

7.  Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tisssue input functions.

Authors:  R V Parsey; M Slifstein; D R Hwang; A Abi-Dargham; N Simpson; O Mawlawi; N N Guo; R Van Heertum; J J Mann; M Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2000-07       Impact factor: 6.200

8.  PET evaluation of [(18)F]FCWAY, an analog of the 5-HT(1A) receptor antagonist, WAY-100635.

Authors:  R E Carson; L Lang; H Watabe; M G Der; H R Adams; E Jagoda; P Herscovitch; W C Eckelman
Journal:  Nucl Med Biol       Date:  2000-07       Impact factor: 2.408

9.  Brain uptake of the acid metabolites of F-18-labeled WAY 100635 analogs.

Authors:  Richard E Carson; Yanjun Wu; Lixin Lang; Ying Ma; Margaret G Der; Peter Herscovitch; William C Eckelman
Journal:  J Cereb Blood Flow Metab       Date:  2003-02       Impact factor: 6.200

10.  Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635.

Authors:  Jussi Hirvonen; Hasse Karlsson; Jaana Kajander; Antti Lepola; Juha Markkula; Helena Rasi-Hakala; Kjell Någren; Jouko K Salminen; Jarmo Hietala
Journal:  Int J Neuropsychopharmacol       Date:  2007-10-31       Impact factor: 5.176

View more
  7 in total

1.  First-in-human evaluation of 18F-mefway, a PET radioligand specific to serotonin-1A receptors.

Authors:  Ansel T Hillmer; Dustin W Wooten; Alisha K Bajwa; Andrew T Higgins; Patrick J Lao; Tobey J Betthauser; Todd E Barnhart; Howard A Rowley; Charles K Stone; Sterling C Johnson; Jogeshwar Mukherjee; Bradley T Christian
Journal:  J Nucl Med       Date:  2014-11-13       Impact factor: 10.057

2.  Serotonin 1A receptors, depression, and memory in temporal lobe epilepsy.

Authors:  William H Theodore; Edythe A Wiggs; Ashley R Martinez; Irene H Dustin; Omar I Khan; Shmuel Appel; Pat Reeves-Tyer; Susumu Sato
Journal:  Epilepsia       Date:  2011-11-02       Impact factor: 5.864

3.  Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography.

Authors:  Kai Kendziorra; Henrike Wolf; Philipp Mael Meyer; Henryk Barthel; Swen Hesse; Georg Alexander Becker; Julia Luthardt; Andreas Schildan; Marianne Patt; Dietlind Sorger; Anita Seese; Herman-Josef Gertz; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-11       Impact factor: 9.236

4.  Autoradiographic evaluation of [3H]CUMI-101, a novel, selective 5-HT1AR ligand in human and baboon brain.

Authors:  J S Dileep Kumar; Ramin V Parsey; Suham A Kassir; Vattoly J Majo; Matthew S Milak; Jaya Prabhakaran; Norman R Simpson; Mark D Underwood; J John Mann; Victoria Arango
Journal:  Brain Res       Date:  2013-02-27       Impact factor: 3.252

5.  Effects of nicotinic acetylcholine receptor agonists on cognition in rhesus monkeys with a chronic cocaine self-administration history.

Authors:  Robert W Gould; Pradeep K Garg; Sudha Garg; Michael A Nader
Journal:  Neuropharmacology       Date:  2012-08-23       Impact factor: 5.250

6.  18F-Mefway PET imaging of serotonin 1A receptors in humans: a comparison with 18F-FCWAY.

Authors:  Jae Yong Choi; Chul Hyoung Lyoo; Jin Su Kim; Kyeong Min Kim; Jee Hae Kang; Soo-Hee Choi; Jae-Jin Kim; Young Hoon Ryu
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

Review 7.  Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target Drugs.

Authors:  Dubravka Svob Strac; Nela Pivac; Ilse J Smolders; Wieslawa A Fogel; Philippe De Deurwaerdere; Giuseppe Di Giovanni
Journal:  Front Neurosci       Date:  2016-11-10       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.